following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
the publication�s purpose is to be a "force for good and a platform for much needed change and to generate critical debate".
.
.
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
.
. may 16, 2018
.
meet other global citizens who care about the same issues you do. keep updated on what they're doing to change the world.